Justin Delgado is husband to Kacie Doyle-Delgado, diagnosed at age 11. After more than a decade together, he considers himself to be an expert carb counter and Dexcom inserter. He graduated with his Master of Science in Finance from the University of Utah in 2013 and has been working in commercial banking since then. He attended his first Friends for Life conference in 2015 and is looking forward to volunteering with the teens.
July 17, 2000
Question from Egg Harbor Township, New Jersey, USA:
I understand there is a new 24 hour long acting insulin which has just been approved for marketing by the FDA. It is Lantus Glargine, made by Hoechst. Will this be a better option than NPH or Ultralente for a 4 year old recently diagnosed Type 1 child? What are your thoughts on the new insulin, and when will it be available by prescription?
Glargine is a new insulin analog that offers a very even release over the 24 hours after injection. Basically it is equivalent to two injections of NPH over the same period; but otherwise affords no striking improvement in control. It is likely to find a place in intensive insulin therapy where it is used with a Humalog dose after meals that is adjusted for the premeal blood sugar and appetite.
[Editor’s comment: Insulin glargine is marketed by Aventis Pharmaceuticals under the brand name Lantus.